KALY Restructures Cannabis Biopharma Business Valued at $50 Million

DALLAS, Dec. 10, 2019 /PRNewswire/ -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ("KALY") today announced the company is restructuring its cannabis biopharmaceutical business as part of a strategy to facilitate a strategic investment at a $50 million valuation.  KALY has a U.S. Patented Cannabis Extraction Process and is developing treatments for various medical conditions (see below).  KALY has recently announced receiving two inquiries into the acquisition of the company's cannabis biopharmaceutical technology valuing the technology at $50 million.  KALY management has recently announced that in response to the two acquisition opportunities, that the company is introducing a third option that would not involve a sale of KALY's biopharmaceutical technology asset but would otherwise restructure the asset under KALY's current corporate umbrella to facilitate a major infusion of investment capital. Today, the company is sharing more details on the restructuring of its cannabis biopharmaceutical business and initiative to infuse investment capital at a $50 million valuation.

As part of a strategy to maintain the long-term sustained development necessary to produce an FDA approved drug, KALY has also introduced a consumer products business utilizing its patented cannabis extraction technology to make CBD infused candies and beverages.  KALY has also introduced a CBD extraction business currently generating revenues under contracts with hemp farmers.  Sales have grown throughout the year from both the CBD infused consumer products business and the CBD extraction business.  KALY management believes the company may realize its first $1 million in annual sales by year end 2019.

KALY acquired a business approximately one year ago that owned the subject patented cannabis extraction process and associated intellectual property.  That acquisition has been the source of KALY's revenue development from CBD infused consumer products and CBD extraction.  The acquisition has also been the source of KALY's published biopharmaceutical developments summarized later in this release.  Now, KALY plans to restructure its cannabis biopharmaceutical assets under a newly formed subsidiary.  The new KALY cannabis biopharmaceutical subsidiary will independently develop investment sources based on the value of the subsidiary itself.  With the recent $50 million valuation confirmed by two independent acquisition offers, combined with an independent fairness opinion now in process, KALY management is confident in securing strategic investment in the new cannabis biopharmaceutical subsidiary that can accelerate the development of KALY's cannabis biopharmaceutical treatments.

KALY's cannabis biopharmaceutical technology intellectual property portfolio contains a deep pipeline of cannabinoid product candidates including four distinct compounds listed here: 

Chronic Obstructive Pulmonary Disease (COPD) - The market for COPD treatment is anticipated to reach $14 billion by 2025;

Type 2 Diabetes - The market for Type 2 Diabetes is expected to be a $64 billion market by 2026;

Cancer Pain Management - The overall pain management treatment market is anticipated to reach $83 billion by 2024, and

Epilepsy - The market for epilepsy treatment is anticipated to reach $9 billion by 2022.

In conjunction with the research already conducted and the next phase of research now moving forward, KALY recently filed for a new patent application specifically on its formulation for symptoms associated with COPD and other similar respiratory conditions.  KALY also filed for a trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions.  The market for COPD treatment is anticipated to reach $14 billion by 2025. 

In addition to KALY's ongoing efforts to develop prescription therapies, KALY has initiated a program to certify its proprietary CBD extracts derived from KALY's U.S. Patented Extraction Process as an Over-The-Counter (OTC) drug under the requirements prescribed by the U.S. Food and Drug Administration. 

To stay abreast of the latest developments and learn more about the company visit  https://www.kali-extracts.com/.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.

CONTACT:
Frederick Ferri
[email protected] 
(214) 210-0459

SOURCE Kali, Inc.